Full Circles Therapeutics
San Francisco, CA
Program data pending ClinicalTrials.gov matching
57.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (7)
○ EMA GMP
○ MHRA GMP
Quick Facts: Full Circles Therapeutics
- Signal Score
- 57.5/100
- Quality Compliance
- Assessment pending
- Headquarters
- San Francisco, CA
- Modalities
- Circular single-stranded DNA (C4DNA / cssDNA / GATALYST platform), Gene editing HDR templates
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Full Circles Therapeutics
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCircular single-stranded DNA (C4DNA / cssDNA / GATALYST platform), Gene editing HDR templates
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
55.0
Manufacturing site information being gathered
Modalities: Circular single-stranded DNA (C4DNA / cssDNA / GATALYST platform), Gene editing HDR templates
Capacity assessment: 55.0/100
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press7 articles
Manufacturing site information being gathered
Modalities: Circular single-stranded DNA (C4DNA / cssDNA / GATALYST platform), Gene editing HDR templates
Capacity assessment: 55.0/100
Recent News 7 articles
How a new tool for large-scale gene editing could power novel genetic medicines - Fierce Biotech
Safer Large DNA Insertion Moves Genetic Medicine Toward Scalability - Genetic Engineering and Biotechnology News
INSTALL Makes Non-Viral Gene Insertion Work In Vivo - CRISPR Medicine News
Circular Single-Stranded DNA Enables Efficient Non-Viral Immune Cell Engineering: Implications for CAR-T Cell Therapy - CRISPR Medicine News
A simpler, single-strand form of DNA may be key to non-viral gene therapy, study suggests - Endpoints News
Highlight: Tripartite complex boosts non-viral gene knock-in accuracy - CRISPR Medicine News
Engineering tripartite gene editing machinery for highly efficient non-viral targeted genome integration - Nature
Frequently Asked Questions About Full Circles Therapeutics
What is Full Circles Therapeutics's CDMO Signal Score?
Full Circles Therapeutics has a Signal Score of 58/100, based on quality, operations, financial stability, and capacity data.
Evaluating Full Circles Therapeutics for a manufacturing program?
Use the free AI matchmaker to compare Full Circles Therapeutics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: